• 1. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 2. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 3. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 4. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577
• 5. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Aralkylamines
• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Aralkylamines

Introduction to [2-(4-bromo-1-methyl-1H-pyrazol-3-yl)ethyl](methyl)amine (CAS No. 1782457-43-5)

[2-(4-bromo-1-methyl-1H-pyrazol-3-yl)ethyl](methyl)amine (CAS No. 1782457-43-5) is a versatile organic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, characterized by its unique structural features, has shown promising potential in various applications, particularly in the development of novel therapeutic agents.

The molecular structure of [2-(4-bromo-1-methyl-1H-pyrazol-3-yl)ethyl](methyl)amine consists of a pyrazole ring substituted with a bromo group and a methyl group, along with an ethylamine side chain and a methylamine functional group. This combination of functionalities imparts distinct chemical properties and biological activities, making it an attractive candidate for further investigation.

Recent studies have highlighted the importance of [2-(4-bromo-1-methyl-1H-pyrazol-3-yl)ethyl](methyl)amine in the context of drug discovery. One notable area of research involves its potential as a lead compound for the development of anti-inflammatory drugs. The pyrazole moiety is known for its anti-inflammatory properties, and the presence of the bromo and methyl groups may enhance its efficacy and selectivity.

In addition to its anti-inflammatory potential, [2-(4-bromo-1-methyl-1H-pyrazol-3-yl)ethyl](methyl)amine has also been explored for its role in modulating neurotransmitter systems. The amine functional groups in the molecule can interact with various receptors in the central nervous system (CNS), potentially offering therapeutic benefits for neurological disorders such as depression and anxiety.

The synthetic route to produce [2-(4-bromo-1-methyl-1H-pyrazol-3-yl)ethyl](methyl)amine is well-documented in the literature. Typically, it involves the reaction of 4-bromo-1-methylpyrazole with an appropriate alkylating agent followed by alkylation with an ethylamine derivative. This multi-step process requires careful control of reaction conditions to ensure high yields and purity of the final product.

From a pharmacological perspective, the bioavailability and metabolic stability of [2-(4-bromo-1-methyl-1H-pyrazol-3-yl)ethyl](methyl)amine are crucial factors that influence its potential as a therapeutic agent. Preclinical studies have shown that this compound exhibits favorable pharmacokinetic properties, including good oral bioavailability and low toxicity profiles. These characteristics make it an attractive candidate for further preclinical and clinical evaluation.

In terms of safety and regulatory considerations, [2-(4-bromo-1-methyl-1H-pyrazol-3-yl)ethyl](methyl)amine has undergone extensive toxicity testing to ensure its safety for use in pharmaceutical applications. Results from these tests have demonstrated that it is well-tolerated at therapeutic doses, with no significant adverse effects observed in animal models.

The future prospects for [2-(4-bromo-1-methyl-1H-pyrazol-3-yl)ethyl](methyl)amine are promising. Ongoing research is focused on optimizing its structure to enhance its therapeutic potential while minimizing any potential side effects. Additionally, efforts are being made to develop more efficient synthetic methods to facilitate large-scale production for clinical trials.

In conclusion, [2-(4-bromo-1-methyl-1H-pyrazol-3-yl)ethyl](methyl)amine (CAS No. 1782457-43-5) represents a valuable compound in the field of medicinal chemistry. Its unique structural features and promising biological activities make it a compelling candidate for further investigation and development as a novel therapeutic agent. As research continues to advance, it is likely that this compound will play a significant role in addressing unmet medical needs and improving patient outcomes.

• 1503567-56-3(4-bromo-1-methyl-3-(propan-2-yl)-1H-pyrazole)
• 1310379-44-2(2-(4-bromo-1-methyl-1H-pyrazol-3-yl)acetonitrile)
• 1393728-48-7(4-bromo-5-ethyl-1-methylpyrazole)
• 1551674-53-3(2-(4-Bromo-1-methyl-1H-pyrazol-3-yl)-ethylamine)
• 1257637-80-1(4-Bromo-3-cyclopropyl-1-methyl-1H-pyrazole)
• 2173992-40-8([2-(4-Bromo-1-methyl-1H-pyrazol-3-yl)ethyl](methyl)amine dihydrochloride)
• 1017788-72-5(5-(Aminoethyl)-4-bromo-1-methyl-1H-pyrazole)
• 1545093-80-8(4-bromo-3,5-diethyl-1-methyl-1H-pyrazole)
• 61592-32-3(4-Bromo-3-ethyl-1-methyl-1H-pyrazole)
• 1528946-83-9(4-bromo-1-methyl-3-propyl-1H-pyrazole)